PARP/MEK dual inhibitors (MD Anderson)

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NamePARP/MEK dual inhibitors (MD Anderson)
Drug Alias Namepoly ADP ribose polymerase/mitogen-activated protein kinase dual inhibitors (MD Anderson)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDual specificity mitogen-activated protein kinase kinase inhibitorsPoly (ADP-Ribose) polymerase inhibitorsGTPase Ras inhibitors
TargetsPoly (ADP-Ribose) polymeraseGTPase RasDual specificity mitogen-activated protein kinase kinase
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesThe University Of Texas MD Anderson Cancer Center
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A